Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Shepherd

Showing results (671-680 of 726) with videos related to

Pageof 73
Sort By:
The New England Journal of Medicine|October 11, 2003
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerPaul E Goss, James N Ingle, Silvana Martino, et al.
Pharmacogenetics and Genomics|July 11, 2020
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancerJames N Ingle, Krishna R Kalari, Poulami Barman, et al.
Cancer Research|October 21, 2016
Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor TherapyJames N Ingle, Fang Xie, Matthew J Ellis, et al.
International Journal of Surgery (London, England)|July 22, 2025
Surgical approach, preoperative LEEP/conization and patterns of recurrence and death in low-risk cervical cancer - exploratory analysis from the CCTG CX.5/SHAPE trialSven Mahner, Fabian Trillsch, Janice S Kwon, et al.
Breast Cancer Research and Treatment|April 3, 2015
Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancerAna Elisa Lohmann, Judy-Anne W Chapman, Margot J Burnell, et al.
Journal of the National Cancer Institute|September 8, 2005
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifenPaul E Goss, James N Ingle, Joseph L Pater, et al.
Breast Cancer Research and Treatment|March 17, 2006
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trialJames N Ingle, Dongsheng Tu, Joseph L Pater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.
BMC Infectious Diseases|July 5, 2022
Etiology of Persistent Microalbuminuria in Nigeria (P_MICRO study): protocol and study designC William Wester, Bryan E Shepherd, Usman J Wudil, et al.
Pageof 73

Showing results (671-680 of 726) with videos related to

Sort By:
Pageof 73
The New England Journal of Medicine|October 11, 2003
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancerPaul E Goss, James N Ingle, Silvana Martino, et al.
Pharmacogenetics and Genomics|July 11, 2020
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancerJames N Ingle, Krishna R Kalari, Poulami Barman, et al.
Cancer Research|October 21, 2016
Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor TherapyJames N Ingle, Fang Xie, Matthew J Ellis, et al.
International Journal of Surgery (London, England)|July 22, 2025
Surgical approach, preoperative LEEP/conization and patterns of recurrence and death in low-risk cervical cancer - exploratory analysis from the CCTG CX.5/SHAPE trialSven Mahner, Fabian Trillsch, Janice S Kwon, et al.
Breast Cancer Research and Treatment|April 3, 2015
Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancerAna Elisa Lohmann, Judy-Anne W Chapman, Margot J Burnell, et al.
Journal of the National Cancer Institute|September 8, 2005
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2008
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifenPaul E Goss, James N Ingle, Joseph L Pater, et al.
Breast Cancer Research and Treatment|March 17, 2006
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trialJames N Ingle, Dongsheng Tu, Joseph L Pater, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2007
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17Paul E Goss, James N Ingle, Silvana Martino, et al.
BMC Infectious Diseases|July 5, 2022
Etiology of Persistent Microalbuminuria in Nigeria (P_MICRO study): protocol and study designC William Wester, Bryan E Shepherd, Usman J Wudil, et al.
Pageof 73